The NanoLiter Reactor sequencing Quick and cost effective method to develop m...
The NanoLiter Reactor sequencing Quick and cost effective method to develop microbial strains
Demand in bioproducts is increasing to answer the food needs required to feed the growing population. The current manufacturing of bioproducts- vitamins, amino acids, industrial enzymes- is heavily relying on the use of fossil fue...
ver más
31/08/2019
FGEN AG
71K€
Presupuesto del proyecto: 71K€
Líder del proyecto
FGEN AG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto FGen
Duración del proyecto: 4 meses
Fecha Inicio: 2019-04-17
Fecha Fin: 2019-08-31
Líder del proyecto
FGEN AG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Demand in bioproducts is increasing to answer the food needs required to feed the growing population. The current manufacturing of bioproducts- vitamins, amino acids, industrial enzymes- is heavily relying on the use of fossil fuels, whereas bio-based production can save water, energy all decreasing waste and costs. The use of efficient microbial strains allows bioproduct manufacturers to do so. The optimization process of the microbial strain is going under several cycles during which culture conditions are modified, and strains genetically modified, making the development long and costly. In addition, the scale-up is often complicated.
FGen has developed a nano-reactor mimicking large bioreactor conditions allowing a high throughput screening of microbial strains, easing the scale-up and speeding the screening of the family strain respectively, all decreasing time and development costs. This nano-reactor having shown promising results, FGen aims to compile it with an innovative method to genetically modified the strains. The combination of these two methods will grant large chemical companies and biotech to save up to 3 years and around €45 M for the development of an efficient strain that will be used in the manufacturing of bioproducts. The estimated segment market for FGen is of €20 bn.
With a time to market estimated at 3 years, FGen aims to act as service provider with external companies to generate revenues and to work on the development of its own strains to license or sold them. FGen estimates to generate a positive EBITDA of €5 M at 7 years (2025), and to grow-up to more than 100 employees.